

Product Datasheet

AS-0141

Catalog No. **BP-01882** · CAS **1402057-88-8** · Form **free base** · Physical state **solid** · Color **White to yellow** · Version **1.0** · Revision **2026-09-07**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target CDK	Research area Cancer
----------------------	--------------------------------

Molecular formula **C₂₁H₂₂F₃N₅O₄**

Molecular weight **465.4257**

STRUCTURE



DESCRIPTION

AS-0141 is a potent Cdc7 kinase inhibitor (IC₅₀=4 nM) extracted from patent WO2019165473A1(compound I- D) with anti-tumor activity.

BIOLOGICAL ACTIVITY

AS-0141 demonstrates potent inhibitory activity (IC₅₀<3 μM) across a variety of solid tumor cell lines, including sarcoma (143B, CADO-ES1, RD-ES, A673), bladder (5673, RT1 12/84), colon and cecum (Colo-205, DLD-1, LS1034, SK-CO-1, SNU-C1), renal (U0.31), melanoma (A2058, A875), head-and-neck (CNE-2Z, RPMI-2650), and gastric (HGC-27) lineages.

SOLUBILITY

Soluble in DMSO

REFERENCES

- [1]. Takayuki Irie, et al. Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers. J Med Chem. 2021 Oct 14;64(19):14153-14164.
- [2]. Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.